Retatrutide is a groundbreaking triple-receptor agonist that targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This novel mechanism positions Retatrutide as a highly effective therapeutic option for managing metabolic disorders, particularly obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).
Developed as a next-generation therapy, Retatrutide has demonstrated remarkable efficacy in clinical trials for weight loss, glycemic control, and metabolic health. It represents a significant advancement in the field of metabolic medicine, with unique benefits stemming from its triple-receptor agonism.
SKU: MAF/RETA/5/10/20/SV/KIT
